Open an account

MediciNova

MNOV · NASDAQ

$1.36−$0.04 (−2.86%)TodayMarket closed ·
Prev close $1.40

About MNOV

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 6 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

Employees
6
Headquarters
La Jolla, California
Listed
Dec 1, 2006
Sector
Health Care
Industry
Biotechnology
Website
medicinova.com

MNOV key statistics

Market cap
66.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
344.28K
Volume
37.13K
Open price
$1.40
High today
$1.44
Low today
$1.36
52 Week high
$3.90
52 Week low
$1.17

MediciNova (MNOV) at a glance

As of Oct 20, 2026, MediciNova (MNOV) shares are priced at $1.36, giving the company a market cap of 66.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.36 and $1.44. The current price is 0.1% above the day's low and 5.6% below its high.

Volume so far is 37.13K shares, below the average of 344.28K shares a day.

Over the past year MediciNova has ranged from $1.17 to $3.90, and now sits 7% of the way up that range.

MediciNova met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.0646.

The average analyst price target is $8.41, 518.7% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $8.41
Low
$6.06
Now
$1.36
High
$11.55

MNOV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 32.8% on average.

  1. Q3 FY24: reported -$0.06 per share against an estimate of -$0.0612
  2. Q4 FY24: reported -$0.06 per share against an estimate of -$0.0561
  3. Q1 FY25: reported -$0.06 per share against an estimate of -$0.1428
  4. Q2 FY25: reported -$0.07 per share against an estimate of -$0.0969
  5. Q3 FY25: reported -$0.06 per share against an estimate of -$0.102
  6. Q4 FY25: reported -$0.05 per share against an estimate of -$0.0969
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0714
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.0646

MNOV news

  • Vandana Singh

    MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseGlobe Newswire

    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

  • Press releaseGlobe Newswire

    MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Similar companies

Companies in the same industry as MediciNova

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.